105 results on '"Sieper, Joachim"'
Search Results
2. Zur Rolle von HLA-B27 in der Pathogenese und Diagnostik der axialen Spondyloarthritis: 50 Jahre nach Entdeckung der starken genetischen Assoziation
3. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
4. Geschichte der Biologikatherapie bei axialer Spondyloarthritis – Teil 2
5. Exploring complement biomarkers in suspected axial spondyloarthritis
6. Impact of body composition on clinical outcomes in patients with active radiographic axial spondyloarthritis under biological therapy
7. Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs
8. Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial
9. The role of HLA-B27 in the pathogenesis and diagnosis of axial spondyloarthritis
10. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five‐Year International Observational Study
11. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature
12. Implementing an automated monitoring process in a digital, longitudinal observational cohort study
13. Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance
14. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five‐Year International Observational Study.
15. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
16. Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
17. Chapter 16 - Spondyloarthritis
18. Intraartikuläres Morphin bei Kniegelenksarthritis – Ergebnisse einer randomisierten placebokontrollierten Studie
19. Eine Therapie mit nicht-steroidalen Antirheumatika ist mit einer Verzögerung der radiografischen Progression der Wirbelsäule bei Patienten mit axialer Spondyloarthritis assoziiert: 10-Jahres-Ergebnisse der GErman SPondyloarthritis Inception Cohort
20. Vergleich des Effekts einer konsequenten Behandlung mit NSAIDs in Kombination mit einer Anti-TNF-Therapie im Vergleich zu einer alleinigen Anti-TNF-Therapie auf das Fortschreiten von strukturellen Schäden an der Wirbelsäule über einen Zeitraum von zwei Jahre bei Patienten mit ankylosierender Spondylitis (CONSUL) – eine offene, randomisierte, kontrollierte, multizentrische Studie
21. Höhere Vitamin-D-Spiegel sind mit einem besseren klinischen Ansprechen auf eine biologische Therapie bei Patienten mit axialer Spondyloarthritis verbunden: Ergebnisse der GESPIC-Kohorte
22. Geschichte der Biologikatherapie bei axialer Spondyloarthritis – Teil 2
23. Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?
24. Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort
25. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time‐Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From the German Spondyloarthritis Inception Cohort
26. The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study
27. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
28. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
29. Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort.
30. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
31. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group
32. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort
33. Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
34. MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacroiliac Joints Typical of Axial Spondyloarthritis
35. OP0149 Radiographic progression from non-radiographic to radiographic axial spondyloarthritis: results from a 5-year multicountry prospective observational study
36. Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
37. What amount of structural damage defines sacroiliitis: a CT study
38. List of contributors
39. A cluster analysis in the worldwide ASAS-PerSpA study
40. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results
41. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
42. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study
43. The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study
44. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results.
45. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
46. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
47. Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis.
48. Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility.
49. What is the optimal target for a T2T approach in axial spondyloarthritis?
50. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.